尼尔塞维马布对重症儿童运输的影响
Carme Alejandre1,2,3, Enrique Pazos1,2, Pablo Gonzalez-Alvarez1,2
1Pediatric Transport Team, Hospital Sant Joan de Déu, 08950 Barcelona, Spain.
Children (Basel, Switzerland)
|February 27, 2026
概括
尼尔西维马布免疫显著减少了支气管炎的儿科运输,特别是与呼吸道同胞病毒 (RSV) 相关的病例. 该计划减少了RSV病例,但没有改变需要转移的儿童的疾病严重程度.
科学领域:
- 儿科 儿科 儿科
- 传染性疾病 传染性疾病
- 公共卫生 公共卫生
背景情况:
- 支气管炎主要是由呼吸道同胞病毒 (RSV) 引起的,是婴儿住院和运输的主要原因.
- 引入单克隆抗体nirsevimab的目的是减少RSV疾病的负担.
- 了解nirsevimab对儿科运输服务的影响对于资源配置和公共卫生战略至关重要.
研究的目的:
- 评估普遍尼尔塞维马布免疫接种对需要专门儿科运输的支气管炎发病率的影响.
- 为了比较临床特征和疾病表型的支气管炎在nirsevimab实施之前和之后.
主要方法:
- 一项描述性观察性研究比较了两个队列:nirsevimab前 (pre-n) 和nirsevimab后 (post-n).
- 收集的数据包括2021年9月至2025年8月期间为支气管炎运输的婴儿的人口统计,临床和微生物信息.
- 使用统计分析来比较两个时期之间的传输率,病毒检测和临床严重程度.
主要成果:
- 在nirsevimab后 (12.4%) 与nirsevimab前 (28.2%) (p < 0.001) 相比,观察到支气管炎运输的显著减少.
- RSV检测率显著下降 (74.3%在n前比47.4%在n后,p<0.001),其他呼吸道病毒的相应增加.
- 在病情严重程度,呼吸支或队列之间停留时间之间没有发现显著差异.
结论:
- 全民尼尔塞维马布免疫接种导致小儿支气管炎的儿科运输量大幅减少,特别是与RSV相关的病例.
- 免疫计划没有改变婴儿中支气管炎的临床严重程度,这些婴儿仍然需要设施间转移.
- 尼尔塞维马布是减少RSV在幼儿中的医疗负担的有效策略.
更多相关视频
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
相关概念视频
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
381
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
381
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
384
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
384
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
336
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
336
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
289
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
289
01:29Drug Dosing: Infants and Children
423
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
423